ViiV to unveil VOGUE head-to-head data pitting Dovato against Gilead's Biktarvy
The Phase 3 VOGUE trial's poster at AIDS 2026 will show whether ViiV's two-drug regimen holds up against Gilead's three-drug standard in previously untreated HIV patients.
Executive Summary
- ViiV Healthcare will present Phase 3 head-to-head data from its VOGUE trial comparing a two-drug oral regimen against Gilead's three-drug standard in adults starting HIV treatment for the first time.
- The trial was built to show whether dropping a third antiretroviral component still suppresses the virus as effectively as the three-drug regimen, including in patients who start treatment with high viral loads.
- The trial closed enrollment below its original target and pushed its completion date out several times, but reached its revised enrollment count and moved to Active, not recruiting, putting Week 48 data within reach of the presentation.
- The result lands in a mechanistically mature field where integrase-inhibitor regimens already dominate first-line HIV treatment, so the presentation extends an established regimen-simplification strategy rather than testing a new mechanism.
The presentation
ViiV Healthcare, the HIV-focused company majority owned by GSK with Shionogi as a shareholder, will present the VOGUE trial's daily-oral Phase 3b data as an in-person poster at the 26th International AIDS Conference in Rio de Janeiro on July 29, 2026. The poster compares Dovato, ViiV's once-daily two-drug regimen of dolutegravir and lamivudine, against Biktarvy, Gilead's once-daily three-drug regimen of bictegravir, emtricitabine and tenofovir alafenamide, in adults with no prior antiretroviral treatment. A companion analysis will examine the study population, including participants with high baseline viral loads, and a separate pooled analysis will look at on-study viremic events across trials comparing the two-drug regimen with three-drug regimens. ViiVViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026Jul 21, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial and its endpoint
The underlying study, registered as NCT05979311 under the acronym VOGUE, is a randomized, open-label Phase 3 trial run across 17 countries including Spain, Germany, Japan and Argentina. Its primary endpoint measures the percentage of participants with plasma HIV-1 RNA below 50 copies per milliliter at Week 48, using the FDA's snapshot algorithm, the standard virologic-suppression measure for first-line HIV registration trials. The trial enrolled 307 patients in a randomized, two-arm design comparing the two regimens head to head, and is registrational. NCT05979311A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05979311
Enrollment and timing
The trial's enrollment target moved several times: an anticipated count of 412 rose to an actual 481 when the trial closed to recruitment in May 2025, then was revised down to 473 in December 2025 and to 307 in the most recent update on July 2, 2026. The primary completion date shifted four times over the trial's life, most recently from March 24, 2026 to April 15, 2026. The trial has been Active, not recruiting since May 2025, consistent with a study that has finished enrolling and is following patients to its Week 48 readout. NCT05979311A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral TherapyNCT05979311
The competitive frame
The comparator, Biktarvy, is approved for treatment-naive and treatment-experienced HIV-1 patients. The field the trial sits in is a mature one: 26 active trials are studying HIV-1 integrase inhibitors in this indication, and the target-indication pair has produced a 10% Phase 3 termination rate across 62 completed and terminated trials, a lower failure rate than in most oncology or immunology settings. ViiV's own two-drug simplification strategy already carries Dovato and the long-acting injectable cabotegravir plus rilpivirine into the market, while Gilead runs multiple next-generation integrase and capsid programs, including bictegravir-lenacapavir combinations and the once-weekly candidate GS-1720, in the same indication. Because the underlying mechanism is validated on both sides, the bar VOGUE has to clear is not proof that integrase inhibition works, but whether removing a third drug from the regimen holds suppression rates in the harder-to-treat, high-viral-load subgroup the trial was designed to isolate.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.